Needham & Company Starts OncoGenex Pharmaceuticals (OGXI) at Buy; Significantly Undervalued; Robust Pipeline
Tweet
Share
E-mailGet Alerts OGXI Hot Sheet
Price: $0.40 --0%
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Join SI Premium – FREE
Needham & Company initiates coverage on OncoGenex Pharmaceuticals (NASDAQ: OGXI) with a Buy. PT $30.00.
Analyst, Chad Messer, said, "The pivotal SYNGERY trial is on track to complete patient enrollment in 4Q:12 with data late next year. We forecast extremely strong Custersin sales in metastatic castrate-resistant prostate cancer (mCRPC) in the U.S. alone, with OncoGenex receiving significant royalties up to the mid-20’s. OncoGenex is also developing wholly-owned OGX-427 in randomized Phase II studies in CRPC and bladder cancer. The CRPC study will report full top line data in 4Q:12 as will a Phase I study in superficial bladder cancer. We view shares of OGXI as significantly undervalued with accelerating news flow and pivotal data in a blockbuster indication less than 6 quarters away."
For an analyst ratings summary and ratings history on OncoGenex Pharmaceuticals click here. For more ratings news on OncoGenex Pharmaceuticals click here.
Shares of OncoGenex Pharmaceuticals closed at $12.58 yesterday.
Analyst, Chad Messer, said, "The pivotal SYNGERY trial is on track to complete patient enrollment in 4Q:12 with data late next year. We forecast extremely strong Custersin sales in metastatic castrate-resistant prostate cancer (mCRPC) in the U.S. alone, with OncoGenex receiving significant royalties up to the mid-20’s. OncoGenex is also developing wholly-owned OGX-427 in randomized Phase II studies in CRPC and bladder cancer. The CRPC study will report full top line data in 4Q:12 as will a Phase I study in superficial bladder cancer. We view shares of OGXI as significantly undervalued with accelerating news flow and pivotal data in a blockbuster indication less than 6 quarters away."
For an analyst ratings summary and ratings history on OncoGenex Pharmaceuticals click here. For more ratings news on OncoGenex Pharmaceuticals click here.
Shares of OncoGenex Pharmaceuticals closed at $12.58 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Upgrades Silicon Labs (SLAB) to Buy
- Craig-Hallum Starts Red Robin Gourmet Burgers (RRGB) at Buy
- DA Davidson Starts Napco Security Technologies, Inc. (NSSC) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
